STOCK TITAN
  1. Home
  2. News
  3. ARDX

Ardelyx to Report Fourth Quarter and Year-End 2021 Financial Results and Provide Corporate Update on February 28, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences earnings

WALTHAM, Mass., Feb. 22, 2022 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative first-in-class medicines that meet significant unmet medical needs, today announced that it will hold a conference call on Monday February 28, at 4:30 pm Eastern Time to discuss fourth quarter and year-end 2021 financial results and provide a corporate update.

To participate in the conference call, please dial (855) 296-9612 (domestic) or (920) 663-6277 (international) and refer to conference ID 2790368. Live audio of the conference call will be simultaneously webcast and will be available under the Investors section of the company's website at www.ardelyx.com. The webcast will be archived and available for replay for 30 days following the call.

About Ardelyx, Inc.

Ardelyx is focused on discovering, developing and commercializing innovative first-in-class medicines to meet significant unmet medical needs. Ardelyx received approval for IBSRELA (tenapanor) with plans to launch in the second quarter of 2022. Ardelyx is developing tenapanor, a novel product candidate to control serum phosphorus in adult patients with CKD on dialysis, which has completed three successful Phase 3 trials. Ardelyx is also advancing RDX013, a potassium secretagogue, for the potential treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease and has an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD.  Ardelyx has established agreements with Kyowa Kirin in Japan, Fosun Pharma in China and Knight Therapeutics in Canada for the development and commercialization of tenapanor in their respective territories.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/ardelyx-to-report-fourth-quarter-and-year-end-2021-financial-results-and-provide-corporate-update-on-february-28-2022-301487152.html

SOURCE Ardelyx

Stock ARDX logo
Ardelyx, Inc.

NASDAQ:ARDX

ARDX Rankings

#2096 Ranked by Market Cap
#88 Ranked by Stock Gains
N/A Ranked by Dividends

ARDX Latest News

May 22, 2024
Ardelyx to Participate at the 2024 Jefferies Global Healthcare Conference
May 21, 2024
Ardelyx Presents Additional Data at the 2024 Digestive Disease Week Conference on IBSRELA® (tenapanor), a First-In-Class Treatment for IBS-C in Adults
May 16, 2024
Ardelyx Presents Additional Data at the NKF 2024 Spring Clinical Meetings on XPHOZAH® (tenapanor)
May 14, 2024
Ardelyx, Inc. Reports Employment Inducement Grants
May 7, 2024
Ardelyx to Present Additional Data Supporting First-In-Class IBSRELA® (tenapanor) for Adults with Irritable Bowel Syndrome with Constipation at the 2024 Digestive Disease Week Conference

ARDX Stock Data

1.58B
226.69M
1.95%
60.33%
15.05%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
FREMONT

About ARDX

ardelyx is focused on enhancing the way people with renal diseases are treated by developing first-in-class medicines. ardelyx's renal pipeline includes the phase 3 development of tenapanor for the treatment of hyperphosphatemia in people with end-stage renal disease who are on dialysis and rdx013, a potassium secretagogue program for the potential treatment of high potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease. in addition, ardelyx has completed phase 3 development of tenapanor for the treatment of irritable bowel syndrome with constipation and anticipates submitting a new drug application to the u.s. food and drug administration for this indication in the second half of 2018. to efficiently bring its treatments to market, ardelyx is pursing strategic collaborations in the u.s. and other countries, including through established agreements with kyowa hakko kirin in japan, fosun pharma in china and knight therapeutics in canada.